These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 26178065)

  • 1. Generation of CD8(+) T cells expressing two additional T-cell receptors (TETARs) for personalised melanoma therapy.
    Höfflin S; Prommersberger S; Uslu U; Schuler G; Schmidt CW; Lennerz V; Dörrie J; Schaft N
    Cancer Biol Ther; 2015; 16(9):1323-31. PubMed ID: 26178065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combining a chimeric antigen receptor and a conventional T-cell receptor to generate T cells expressing two additional receptors (TETARs) for a multi-hit immunotherapy of melanoma.
    Uslu U; Schuler G; Dörrie J; Schaft N
    Exp Dermatol; 2016 Nov; 25(11):872-879. PubMed ID: 27246630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RNA-transfection of γ/δ T cells with a chimeric antigen receptor or an α/β T-cell receptor: a safer alternative to genetically engineered α/β T cells for the immunotherapy of melanoma.
    Harrer DC; Simon B; Fujii SI; Shimizu K; Uslu U; Schuler G; Gerer KF; Hoyer S; Dörrie J; Schaft N
    BMC Cancer; 2017 Aug; 17(1):551. PubMed ID: 28818060
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhancing lentiviral transduction to generate melanoma-specific human T cells for cancer immunotherapy.
    Simon B; Harrer DC; Thirion C; Schuler-Thurner B; Schuler G; Uslu U
    J Immunol Methods; 2019 Sep; 472():55-64. PubMed ID: 31207210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polyfunctional response by ImmTAC (IMCgp100) redirected CD8
    Boudousquie C; Bossi G; Hurst JM; Rygiel KA; Jakobsen BK; Hassan NJ
    Immunology; 2017 Nov; 152(3):425-438. PubMed ID: 28640942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic TCR-MHC (self)-interactions limit the functional potential of TCR affinity-increased CD8 T lymphocytes.
    Duong MN; Erdes E; Hebeisen M; Rufer N
    J Immunother Cancer; 2019 Nov; 7(1):284. PubMed ID: 31690351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of optimal bicistronic lentiviral vectors facilitates high-level TCR gene expression and robust tumor cell recognition.
    Yang S; Cohen CJ; Peng PD; Zhao Y; Cassard L; Yu Z; Zheng Z; Jones S; Restifo NP; Rosenberg SA; Morgan RA
    Gene Ther; 2008 Nov; 15(21):1411-23. PubMed ID: 18496571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. T-cell clones from melanoma patients immunized against an anchor-modified gp100 peptide display discordant effector phenotypes.
    Dudley ME; Ngo LT; Westwood J; Wunderlich JR; Rosenberg SA
    Cancer J; 2000; 6(2):69-77. PubMed ID: 11069222
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Arming T Cells with a gp100-Specific TCR and a CSPG4-Specific CAR Using Combined DNA- and RNA-Based Receptor Transfer.
    Simon B; Harrer DC; Schuler-Thurner B; Schuler G; Uslu U
    Cancers (Basel); 2019 May; 11(5):. PubMed ID: 31137488
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens.
    Morgan RA; Dudley ME; Yu YY; Zheng Z; Robbins PF; Theoret MR; Wunderlich JR; Hughes MS; Restifo NP; Rosenberg SA
    J Immunol; 2003 Sep; 171(6):3287-95. PubMed ID: 12960359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. T-cell receptor gene therapy of established tumors in a murine melanoma model.
    Abad JD; Wrzensinski C; Overwijk W; De Witte MA; Jorritsma A; Hsu C; Gattinoni L; Cohen CJ; Paulos CM; Palmer DC; Haanen JB; Schumacher TN; Rosenberg SA; Restifo NP; Morgan RA
    J Immunother; 2008 Jan; 31(1):1-6. PubMed ID: 18157006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Engineering Cancer Antigen-Specific T Cells to Overcome the Immunosuppressive Effects of TGF-β.
    Silk JD; Abbott RJM; Adams KJ; Bennett AD; Brett S; Cornforth TV; Crossland KL; Figueroa DJ; Jing J; O'Connor C; Pachnio A; Patasic L; Peredo CE; Quattrini A; Quinn LL; Rust AG; Saini M; Sanderson JP; Steiner D; Tavano B; Viswanathan P; Wiedermann GE; Wong R; Jakobsen BK; Britten CM; Gerry AB; Brewer JE
    J Immunol; 2022 Jan; 208(1):169-180. PubMed ID: 34853077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Persistence of CTL clones targeting melanocyte differentiation antigens was insufficient to mediate significant melanoma regression in humans.
    Chandran SS; Paria BC; Srivastava AK; Rothermel LD; Stephens DJ; Dudley ME; Somerville R; Wunderlich JR; Sherry RM; Yang JC; Rosenberg SA; Kammula US
    Clin Cancer Res; 2015 Feb; 21(3):534-43. PubMed ID: 25424856
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Redirecting human CD4+ T lymphocytes to the MHC class I-restricted melanoma antigen MAGE-A1 by TCR alphabeta gene transfer requires CD8alpha.
    Willemsen R; Ronteltap C; Heuveling M; Debets R; Bolhuis R
    Gene Ther; 2005 Jan; 12(2):140-6. PubMed ID: 15496961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human T cells expressing two additional receptors (TETARs) specific for HIV-1 recognize both epitopes.
    Hofmann C; Höfflin S; Hückelhoven A; Bergmann S; Harrer E; Schuler G; Dörrie J; Schaft N; Harrer T
    Blood; 2011 Nov; 118(19):5174-7. PubMed ID: 21926350
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimizing T-cell receptor avidity with somatic hypermutation.
    Bassan D; Gozlan YM; Sharbi-Yunger A; Tzehoval E; Eisenbach L
    Int J Cancer; 2019 Nov; 145(10):2816-2826. PubMed ID: 31381134
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generation of tumor antigen-specific murine CD8+ T cells with enhanced anti-tumor activity via highly efficient CRISPR/Cas9 genome editing.
    Ouchi Y; Patil A; Tamura Y; Nishimasu H; Negishi A; Paul SK; Takemura N; Satoh T; Kimura Y; Kurachi M; Nureki O; Nakai K; Kiyono H; Uematsu S
    Int Immunol; 2018 Apr; 30(4):141-154. PubMed ID: 29617862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of IL-21 and IL-15 enhances tumour-specific cytotoxicity and cytokine production of TCR-transduced primary T cells.
    Pouw N; Treffers-Westerlaken E; Kraan J; Wittink F; ten Hagen T; Verweij J; Debets R
    Cancer Immunol Immunother; 2010 Jun; 59(6):921-31. PubMed ID: 20101507
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The siRNA-mediated downregulation of PD-1 alone or simultaneously with CTLA-4 shows enhanced in vitro CAR-T-cell functionality for further clinical development towards the potential use in immunotherapy of melanoma.
    Simon B; Harrer DC; Schuler-Thurner B; Schaft N; Schuler G; Dörrie J; Uslu U
    Exp Dermatol; 2018 Jul; 27(7):769-778. PubMed ID: 29704887
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Molecular Switch Abrogates Glycoprotein 100 (gp100) T-cell Receptor (TCR) Targeting of a Human Melanoma Antigen.
    Bianchi V; Bulek A; Fuller A; Lloyd A; Attaf M; Rizkallah PJ; Dolton G; Sewell AK; Cole DK
    J Biol Chem; 2016 Apr; 291(17):8951-9. PubMed ID: 26917722
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.